Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (Lisocabtagene Maraleucel) for Relapsed or Refractory Large B-cell Lymphoma after One Prior Therapy

Bristol Myers Squibb announced that the European Commission has granted approval for Breyanzi, a CD19-directed CAR T cell therapy, for relapsed or refractory large B cell lymphoma after one prior therapy.